AstraZeneca announced today they have reached an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII). In this $750M agreement, AstraZeneca will produce 300M doses by the end of 2020.
In addition to these 300M doses, the group has reached a licensing agreement with SII where they plan to deliver 1B doses for low/middle-income countries. By the end of 2020, they'll have reached their first target of 400M doses.
This news comes at the heels of a recent announcement to produce 400M doses of COVID-19 vaccine to the US/UK in partnership with Oxford University. Oxford is working on a recombinant adenovirus vaccine called AZD1222 (formerly ChAdOx1 nCoV-19). Progress for this vaccine have already started in the Phase II/III stage.
See the progress of vaccine development across manufacturers on our progress page. Updated daily.
To achieve these lofty goals, the company committed to an existing manufacturing capacity of 2B doses across supply chains around the world. These supply chains will produce vaccines for low/middle-income countries without profit.